discov
new
treatment
cryptosporidiosi
assembl
set
compound
known
activ
variou
protozoan
parasit
screen
c
parvum
high
content
imag
infect
assay
cell
see
supplementari
materi
notabl
mani
antimalari
lack
activ
cryptosporidium
howev
compound
show
growth
inhibit
secondari
screen
use
novel
cytopath
effect
cpe
base
c
parvum
assay
confirm
sever
scaffold
show
submicromolar
cellular
activ
fig
tabl
structur
provid
extend
data
evalu
pyrazolopyridin
analog
found
correl
activ
c
parvum
plasmodium
falciparum
fig
suggest
mechan
action
pyrazolopyridin
conserv
two
parasit
correl
observ
toxic
extend
data
fig
c
homini
respons
major
clinic
thu
evalu
subset
pyrazolopyridin
analog
c
homini
found
potenc
compar
c
parvum
fig
tabl
know
pyrazolopyridin
imidazopyrazin
exert
antimalari
activ
inhibit
plasmodium
lipid
kinas
pi
k
search
potenti
cryptosporidium
ortholog
genom
c
parvum
c
homini
encod
multipl
put
lipid
kinas
pi
k
catalyt
domain
c
homini
homolog
show
amino
acid
sequenc
similar
p
falciparum
pi
k
express
insect
cell
purifi
protein
cppi
k
display
phosphatidylinositol
pi
kinas
activ
km
atp
pi
respect
extend
data
fig
use
assay
show
imidazopyrazin
pyrazolopyridin
potent
inhibitor
cppi
k
enzymat
activ
valu
nm
respect
fig
compound
fold
select
window
human
pi
k
homologu
extend
data
tabl
measur
divers
imidazopyrazin
pyrazolopyridin
analog
cppi
k
enzymat
activ
c
parvum
growth
cell
found
tight
correl
fig
suggest
anticryptosporidium
activ
directli
mediat
cppi
k
inhibit
genet
structur
insight
need
unambigu
establish
k
target
howev
note
plasmodium
pi
k
inhibitor
diarylaminopyridin
quinoxalin
inact
c
parvum
c
homini
inhibit
cppi
k
enzymat
activ
fig
final
mechanist
studi
reveal
increas
km
atp
presenc
fig
suggest
atpcompetit
inhibit
similarli
previous
observ
plasmodium
addit
structureact
relationship
analysi
pyrazolopyridin
cryptosporidium
found
supplementari
inform
taken
togeth
data
suggest
pyrazolopyridin
inhibitor
cppi
k
bind
atpbind
site
enzym
favor
select
window
human
pi
k
urgent
need
effect
cryptosporidiosi
treatment
among
children
age
two
safe
drug
profil
thu
key
compon
target
product
select
index
cpcpe
extend
data
tabl
batteri
safeti
pharmacolog
assay
compound
show
intrins
risk
cardiotox
mutagen
clastogen
phototox
significantli
bind
panel
human
antitarget
extend
data
tabl
safeti
evalu
toxicolog
studi
rat
use
solid
dispers
formul
maxim
system
exposur
fold
studi
signific
histopatholog
chang
minor
chang
clinic
chemistri
hematolog
observ
slight
elev
chlorid
phosphat
ion
increas
red
blood
cell
see
supplementari
materi
importantli
hematopoiet
toxic
relat
potenti
inhibit
lipid
kinas
observ
suggest
vitro
select
translat
lack
host
toxic
vivo
extend
data
tabl
children
cryptosporidiosi
resourc
limit
set
frequent
suffer
comorbid
includ
hiv
tb
infect
anticryptosporidi
drug
thu
like
use
along
medic
risk
drugdrug
interact
need
minim
consist
requir
inhibit
major
cytochrom
isoenzym
induc
human
pregnan
x
receptor
extend
data
tabl
pharmacokinet
metabol
distribut
examin
mice
rat
rhesu
monkey
upon
intraven
administr
display
low
moder
volum
distribut
vss
literkg
low
total
system
clearanc
cl
mlmin
kg
halflif
rang
hour
extend
data
tabl
orallyadminist
suspens
formul
display
moder
halflif
h
three
speci
select
drug
candid
show
moderatetolow
oral
bioavail
rodent
nonhuman
primat
cryptosporidium
primarili
infect
intestin
epithelium
reason
system
exposur
may
requir
efficaci
limit
system
exposur
may
enhanc
safeti
margin
cryptosporidiosi
drug
current
assess
cryptosporidiosi
treatment
reli
labori
method
quantifi
parasit
anim
use
geneticallymodifi
parasit
build
facil
model
establish
transgen
use
nanoluciferas
nluc
readout
found
compar
wildtyp
parasit
extend
data
fig
next
inocul
week
old
mice
oocyst
monitor
infect
follow
parasitederiv
luciferas
activ
fece
fig
infect
mice
treat
oral
suspens
formul
parasit
load
measur
pool
fece
nluc
quantit
pcr
assay
high
degre
correl
spearman
two
tail
nluc
assay
small
sampl
requir
mg
thu
could
conduct
individu
mice
well
pool
fece
unpair
ttest
compar
mean
individu
pool
read
show
signific
differ
twotail
importantli
dramat
reduc
oocyst
shed
regardless
assay
method
fig
extend
data
fig
c
nonparametr
kruskalw
test
pool
nluc
twotail
p
fecal
qpcr
twotail
modifi
design
mgkg
treatment
initi
peak
infect
result
signific
reduct
oocyst
shed
fig
c
end
treatment
period
three
mice
per
group
kill
intestin
process
histolog
observ
parasit
intestin
treat
anim
receiv
vehicl
show
substanti
infect
fig
dynam
evalu
impact
treatment
parasit
load
directli
intestin
tissu
engin
new
report
parasit
amen
detect
wholeanim
imag
mice
infect
parasit
express
redshift
firefli
fluc
imag
follow
dluciferin
inject
intestin
tissu
load
quantifi
pcr
found
strong
correl
tissu
luminesc
extend
data
fig
b
c
treatment
mice
infect
fluc
parasit
initi
day
mice
regist
high
level
abdomin
luciferas
activ
mice
imag
daili
tissu
load
drop
markedli
within
day
treatment
fell
limit
detect
five
day
fig
g
chang
luminesc
imag
mirror
fecal
oocyst
shed
quantifi
pcr
spearman
coeffici
twotail
p
extend
data
fig
comparison
evalu
nitazoxanid
mgkg
observ
chang
fig
extend
data
fig
consist
previou
report
immunosuppress
newborn
calv
natur
suscept
c
parvum
infect
result
fecal
oocyst
shed
profus
wateri
diarrhea
sever
dehydr
close
mirror
human
challeng
neonat
calv
x
oocyst
durat
enrol
complet
physic
examin
perform
everi
h
clinic
data
includ
appetit
mentat
fecal
consist
hydrat
statu
record
fig
assign
clinic
score
scale
normal
sever
accord
previous
describ
method
see
rubric
supplementari
inform
fecal
oocyst
shed
enumer
everi
h
qpcr
treatment
group
n
subject
oral
treatment
mgkg
suspens
formul
everi
h
day
treatment
initi
upon
develop
fulmin
diarrhea
fecal
oocyst
shed
day
day
postinfect
calv
toler
treatment
without
compound
relat
abnorm
treat
calv
shed
significantli
fewer
oocyst
vehicl
treat
calv
within
day
treatment
p
day
fig
treat
calv
suffer
fewer
day
sever
diarrhea
twotail
p
significantli
less
dehydr
twotail
p
control
fig
resolut
clinic
sign
commenc
earli
h
treatment
initi
within
h
treatment
calv
show
sign
dehydr
within
h
treatment
calv
resolut
sever
diarrhea
extend
data
fig
display
limit
system
exposur
calv
cmax
auc
respect
fig
extend
data
tabl
confirm
substanti
system
exposur
may
requir
parasit
clearanc
resolut
clinic
ill
studi
defin
pyrazolopyridin
promis
anticryptosporidi
drug
candid
activ
c
parvum
c
homini
unlik
nitazoxanid
demonstr
vivo
efficaci
immunocompromis
mice
addit
treatment
neonat
calv
close
match
pathophysiolog
pharmacolog
challeng
face
treatment
young
malnourish
children
led
signific
decreas
parasit
shed
rapid
resolut
diarrhea
dehydr
lead
candid
display
good
anticryptosporidi
activ
meet
broad
rang
safeti
pharmacolog
criteria
requir
much
need
novel
cryptosporidiosi
therapeut
intervent
safeti
pharmacolog
preclin
evalu
current
ongo
support
initi
human
clinic
trial
synthes
describ
synthesi
pyrazolopyridin
analog
describ
supplementari
inform
patent
human
ileocec
adenocarcinoma
cell
purchas
atcc
test
mycoplasma
nitd
uga
maintain
medium
supplement
heatinactiv
hors
serum
c
parvum
c
homini
oocyst
purchas
sterl
laboratori
univers
arizona
tuft
univers
cum
school
veterinari
medicin
oocyst
use
infect
experi
less
three
month
date
shed
excyst
infect
protocol
follow
establish
method
oocyst
treat
mm
hydrochlor
acid
hcl
hank
balanc
salt
solut
hbss
minut
agit
wash
twice
nonacid
hbss
oocyst
excyst
densiti
prime
parasit
infect
medium
leibovitz
medium
ultracultur
medium
supplement
mm
sodium
taurochol
heatinactiv
hors
serum
lascorb
acid
dilut
subsequ
assay
perform
parasit
infect
medium
without
sodium
taurochol
previous
report
c
parvum
hci
assay
cell
use
modif
describ
detail
supplementari
inform
high
content
imag
cell
infect
assay
c
parvum
c
homini
conduct
follow
establish
flat
black
clearbottom
plate
use
opera
qeh
imag
system
also
develop
cytopath
effect
cpe
base
assay
monitor
host
cell
viabil
use
ctg
reagent
promega
requir
stain
imag
detail
determin
c
parvum
c
homini
use
assay
doserespons
compound
dilut
describ
also
determin
use
nluc
express
briefli
cell
infect
purifi
nluc
express
parasit
oocyst
per
well
incub
differ
concentr
hour
cultur
supernat
remov
well
ul
nanoglo
lysi
buffer
contain
nanoglo
substrat
promega
corpor
ad
well
lysat
transfer
well
plate
luminesc
measur
synergi
hybrid
micropl
reader
biotek
instrument
cytotox
atcc
determin
previous
cell
seed
well
plate
cell
per
well
incub
hour
expos
threefold
seriallydilut
compound
hour
cell
viabil
monitor
use
cell
count
fulllength
code
sequenc
c
parvum
pi
k
codonoptim
baculoviru
express
synthes
clone
pfastbachtb
invitrogen
frame
aminotermin
polyhistidin
tag
use
bamhi
hindiii
restrict
site
recombin
pfastbachtbcppi
k
bacmid
clone
gener
sitespecif
transposit
e
coli
invitrogen
bacmid
sequenc
confirm
direct
dna
sequenc
bacmid
isol
transfect
select
recombin
virus
perform
accord
manufactur
protocol
bactobac
system
invitrogen
cell
cultur
iii
serumfre
medium
transfect
recombin
baculoviru
vv
incub
h
pellet
collect
centrifug
resuspend
cell
lysi
buffer
mm
trishcl
ph
mm
nacl
dtt
imidazol
triton
complet
proteas
inhibitor
cocktail
without
edta
roch
diagnost
cell
suspens
lyse
sonic
clarifi
supernat
load
onto
ml
histrap
affin
column
ge
healthcar
preequilibr
buffer
mm
trishcl
ph
mm
nacl
dtt
imidazol
complet
proteas
inhibitor
cocktail
without
edta
column
wash
buffer
contain
mm
imidazol
bound
protein
elut
buffer
mm
imidazol
fraction
contain
cppi
k
pool
concentr
use
amicon
purifi
gelfiltr
column
hiload
superdex
ge
healthcar
equilibr
mm
tri
ph
mm
nacl
mm
dtt
proteas
inhibitor
cocktail
without
edta
aliquot
flash
frozen
liquid
nitrogen
immedi
store
mutat
introduc
cppi
k
pfastbac
plasmid
use
quikchang
sitedirect
mutagenesi
kit
agil
confirm
dna
sequenc
mutant
protein
express
purifi
assay
describ
wildtyp
protein
show
signific
chang
see
supplementari
materi
full
detail
cppi
k
enzym
assay
describ
briefli
avanti
polar
lipid
dissolv
noctylglucosid
roch
diagnost
use
lipid
substrat
use
transcreen
fp
detect
kit
bellbrook
lab
black
solid
plate
corn
final
assay
volum
contain
nm
cppi
k
mm
tri
ph
mm
dtt
atp
mm
triton
phosphatidylinositoloctylglucosid
enzym
reaction
perform
min
room
temperatur
stop
ad
detect
mix
contain
hepe
nacl
edta
nm
amp
alexa
fluor
tracer
adp
antibodi
bellbrook
lab
fluoresc
polar
measur
perform
infinit
plate
reader
tecan
nm
nm
bandwidth
valu
calcul
use
graphpad
prism
softwar
solubl
measur
use
miniatur
shakeflask
approach
streamlin
hplc
analysi
describ
parallel
artifici
membran
assay
carri
use
standard
metabol
stabil
liver
microsom
determin
use
compound
deplet
approach
quantifi
lcm
assay
measur
rate
extent
metabol
determin
disappear
parent
compound
allow
determin
vitro
halflif
intrins
clearanc
predict
metabol
clearanc
variou
cardiotox
miniam
risk
measur
previous
assay
bind
protein
known
bear
potenti
safeti
liabil
human
highthroughput
competit
bind
assay
use
specif
radiolabel
phototox
assay
perform
follow
oecd
guidelin
test
chemic
vitro
nru
phototox
test
subject
inhibit
analysi
use
differ
compound
assess
time
depend
inhibit
use
cyp
induct
assay
carri
use
pxr
receptor
bind
assay
use
lanthascreen
trfret
pxr
sxr
competit
bind
assay
kit
rodent
vivo
pk
analysi
conduct
use
nonrandom
femal
mice
n
week
old
wister
rat
n
week
old
pk
studi
monkey
n
perform
rhesu
macaqu
neonat
calf
pk
studi
perform
part
efficaci
studi
day
day
treatment
procedur
involv
anim
review
approv
respect
institut
anim
care
use
committe
formul
suspens
formul
po
dose
solut
formul
iv
dose
describ
extend
data
tabl
rat
toxicolog
studi
formul
solid
dispers
sd
requir
excipi
soluplu
eudragit
e
po
sl
dissolv
ethanoldichloromethan
total
solid
concentr
sonic
heat
solut
spray
dri
use
buchi
mini
spray
dryer
inlet
temperatur
aspir
set
pump
follow
overnight
dri
vacuum
amorph
natur
confirm
xray
powder
diffract
analysi
powder
store
sd
powder
suspens
prepar
freshli
hpmc
acet
buffer
mgml
equival
sd
powder
rat
dose
within
one
hour
prepar
blood
sampl
pk
studi
collect
h
post
dose
compound
plasma
concentr
determin
lcm
plasma
sampl
pharmacokinet
studi
extract
acetonitril
methanol
acet
acid
contain
warfarin
intern
standard
use
extract
plasma
ratio
analyt
quantit
perform
lcmsm
liquid
chromatographi
perform
use
agil
hplc
system
agil
zorbax
phenyl
mm
column
oven
temperatur
coupl
tripl
quadrupl
mass
spectromet
appli
biosystem
pk
paramet
determin
use
watson
lim
noncompartment
analysi
solid
dispers
powder
suspens
prepar
freshli
hpmc
acet
buffer
mgml
oral
administ
male
wistar
rat
daili
oral
dose
mgkgday
two
week
five
control
anim
treat
vehicl
rat
obtain
shanghai
slac
anim
ltd
subject
day
quarantin
acclimat
prior
studi
begin
anim
subject
daili
clinic
observ
bodi
weight
food
consumpt
determin
anim
enrol
studi
clinic
laboratori
evalu
hematolog
clinic
chemistri
perform
schedul
necropsi
day
organ
examin
gross
patholog
weigh
prior
fixat
prepar
histolog
sampl
organ
tissu
prepar
anim
assign
control
high
dose
group
examin
microscop
specif
heart
pancrea
gastrointestin
tract
oesophagu
stomach
duodenum
jejunum
ileum
caecum
colon
rectum
kidney
liver
spleen
lung
test
epididymi
adren
thymu
examin
histopatholog
chang
utr
utr
c
parvum
actin
gene
amplifi
parasit
genom
dna
ligat
kpniclai
speibamhi
site
plasmid
tkenonlucneotk
respect
code
sequenc
redshift
amplifi
vector
kind
gift
marku
meissner
univers
glasgow
clone
salinhei
restrict
site
replac
nluc
bp
fragment
tk
flank
tk
gene
ribosom
utr
insert
upstream
actin
utr
use
gibson
assembl
clone
new
england
biolab
final
vector
along
plasmid
contain
tk
guid
rna
gaagaatacaatttctaagg
target
end
tk
gene
use
transfect
c
parvum
sporozoit
sporozoit
deliv
via
surgeri
small
intestin
knockout
mice
jackson
laboratori
use
procedur
describ
note
nluc
parasit
gener
use
c
parvum
iowa
ii
oocyst
purchas
sterl
parasitolog
laboratori
univers
arizona
wherea
fluc
strain
engin
use
c
parvum
iowa
ii
oocyst
purchas
bunch
grass
farm
deari
id
mous
studi
describ
section
approv
institut
anim
care
use
committe
univers
georgia
anim
use
protocol
mice
age
week
select
randomli
group
infect
c
parvum
oocyst
statist
test
use
predetermin
sampl
size
formul
wv
methylcellulos
wv
polysorb
water
administ
mice
daili
day
oral
gavag
begin
day
day
postinfect
control
mice
given
vehicl
mice
monitor
weight
loss
fur
ruffl
hunch
postur
inact
mice
show
weight
loss
euthan
fecal
sampl
collect
blind
luminesc
measur
perform
parasit
nluc
activ
stabl
fece
refriger
measur
perform
fece
collect
individu
mice
well
cagewid
pool
collect
nluc
assay
mg
fece
mash
ml
lysi
buffer
trishcl
dtt
edta
glycerol
tritonx
ten
mm
glass
bead
ad
tube
follow
vigor
agit
use
vortex
mixer
minut
short
spin
pellet
fecal
materi
three
aliquot
lysat
dispens
well
white
plate
equal
amount
nanoglo
reconstitut
buffer
contain
nanoglo
substrat
promega
ad
luminesc
read
use
synergi
hybrid
micropl
reader
biotek
instrument
measur
oocyst
load
quantit
realtim
pcr
qrtpcr
dna
isol
mg
fece
sampl
subject
five
round
freez
liquid
nitrogen
thaw
heater
block
prior
dna
isol
use
zr
fecal
dna
miniprep
kit
zymo
research
corp
irvin
ca
qrtpcr
perform
use
sampl
dna
along
standard
prepar
uninfect
fece
spike
oocyst
pcr
primer
jvaf
javr
probe
fam
label
use
along
follow
cycl
paramet
denatur
min
follow
cycl
denatur
sec
anneal
sec
pcr
reaction
contain
univers
probe
supermix
biorad
laboratori
hercul
ca
primer
probe
dna
mice
per
group
infect
c
parvum
fluc
oocyst
express
redshift
firefli
luciferas
given
daili
dose
mgkg
nitazoxanid
sigma
control
formul
one
week
oral
gavag
start
day
postinfect
parasit
tissu
load
measur
vivo
imag
begin
experi
abdomin
area
mice
shave
clipper
increas
signal
imag
ivi
lumina
ii
system
calip
life
scienc
mice
inject
subcutan
mgkg
dluciferin
gold
biotechnolog
inc
st
loui
mo
usa
minut
luciferin
inject
mice
anaesthet
induct
chamber
use
isofluoran
place
camera
chamber
mice
kept
anesthesia
administ
isofluoran
individu
nose
cone
imag
acquir
use
set
bin
medium
exposur
time
minut
region
interest
roi
select
mous
total
flux
photonssec
quantifi
use
ivi
lumina
ii
live
imag
softwar
calip
life
scienc
valid
measur
parasit
tissu
burden
mice
infect
one
week
imag
kill
small
intestin
remov
cut
cm
segment
flush
pb
section
imag
time
pb
dluciferin
genom
dna
isol
segment
use
zr
fecal
dna
miniprep
kit
zymo
research
corp
irvin
ca
qpcr
perform
use
paramet
describ
parasit
burden
establish
standard
curv
sampl
known
parasit
dna
content
mice
treat
control
formul
kill
intestin
tissu
collect
within
minut
death
section
small
intestin
taken
cm
region
anterior
cecum
flush
pb
fix
overnight
buffer
formalin
fix
sampl
embed
paraffin
section
cut
microtom
leica
buffalo
grove
il
section
deparafin
stain
hematoxylin
eosin
calv
use
studi
care
complianc
washington
state
univers
institut
anim
care
use
committe
sampl
size
calcul
assum
treat
calv
resolut
clinic
ill
end
treatment
period
hr
postadministr
treatment
compar
control
calv
assum
type
error
risk
type
ii
error
risk
calv
need
treatment
group
plu
posit
control
event
calf
death
remov
studi
addit
calv
ad
control
group
n
sampl
size
calcul
use
epi
info
fifteen
friesianholstein
bull
calv
enrol
novemb
februari
birth
calv
enrol
novemb
random
treatment
n
posit
infect
control
n
neg
infect
control
n
calv
enrol
februari
posit
control
perineum
dam
clean
scrub
calv
deliv
onto
singleus
plastic
sheet
prevent
exposur
environment
pathogen
calv
abnorm
physic
examin
find
weigh
less
kg
birth
exclud
enrol
calv
receiv
iggl
commerci
colostrum
replac
land
lake
inc
ml
subcutan
inject
vitamin
e
selenium
merck
anim
health
calv
transport
commerci
dairi
farm
washington
state
univers
hous
individu
box
stall
facil
shatterproof
mirror
provid
enrich
within
h
birth
blood
sampl
collect
evalu
adequ
passiv
transfer
colostr
immun
calv
offer
commerci
fat
nonmed
milk
replac
land
lake
inc
everi
h
via
nippl
bucket
feed
calv
fed
averag
g
dri
matter
per
kg
birth
weight
durat
studi
water
provid
ad
libitum
calv
random
treatment
posit
control
group
experiment
challeng
within
first
h
life
c
parvum
oocyst
iowa
ii
bunch
grass
farm
id
via
rigid
portion
oroesophag
feed
tube
oocyst
within
month
isol
clean
sodium
hypochlorit
minut
wash
four
time
pb
neg
control
calf
shamchalleng
maintain
blind
studi
personnel
facilit
collect
blood
plasma
pharmacokinet
analysi
longterm
intraven
cathet
milacath
mila
intern
asept
place
jugular
vein
within
first
hour
life
calv
sedat
xylazin
ml
iv
akorn
anim
health
sedat
revers
atipamezol
im
zoeti
begin
birth
fecal
sampl
collect
directli
rectum
everi
h
complet
physic
exam
perform
everi
h
clinic
data
includ
appetit
mentat
fecal
consist
hydrat
statu
record
clinic
data
evalu
scale
normal
sever
accord
previous
describ
method
see
rubric
supplementari
inform
prepar
suspens
formul
wv
methylcellulos
wv
water
treatment
initi
calf
began
shed
oocyst
fecal
consist
score
calv
induc
suckl
given
oral
via
oral
dose
syring
calv
treat
everi
h
day
dose
mgkg
birth
weight
least
h
feed
pharmacokinet
sampl
conduct
day
day
treatment
blood
drawn
prior
multipl
timepoint
follow
administr
fecal
sampl
collect
h
h
follow
administr
day
treatment
blood
collect
prior
administr
day
life
fecal
sampl
test
e
coli
day
salmonella
rotaviru
corona
viru
treatment
calv
two
calv
randomli
select
euthan
hour
administr
final
treatment
posit
control
calf
also
euthan
time
euthanasia
via
captiv
bolt
induct
bilater
pneumothorax
order
avoid
confound
histolog
find
calv
submit
necropsi
washington
state
anim
diseas
diagnost
laboratori
sampl
liver
spleen
kidney
small
intestin
collect
histolog
analysi
remain
calv
continu
studi
cessat
fecal
oocyst
shed
determin
immunofluoresc
microscopi
merifluor
meridian
diagnost
upon
cessat
fecal
oocyst
shed
consecut
neg
fecal
sampl
h
calv
euthan
submit
washington
state
anim
diseas
diagnost
laboratori
necropsi
oocyst
count
interpol
qrtpcr
cornel
anim
health
diagnost
center
use
serial
dilut
commerci
purifi
c
parvum
oocyst
waterborn
inc
new
orlean
la
total
nucleic
acid
extract
supernat
mg
fecal
sampl
oocyst
suspens
neg
control
homogen
pb
use
magnet
bead
base
autom
procedur
appli
biosytem
foster
citi
ca
exogen
control
phage
ad
lysi
buffer
control
pcr
qpcr
cryptosporidium
spp
rrna
perform
appli
biosystem
platform
use
commerci
master
mix
toughmix
quantabio
oligonucleotid
previous
count
standard
fecal
dri
weight
percentag
g
portion
origin
fecal
sampl
dri
minimum
h
squaroid
vaccuum
oven
lablin
india
data
analyz
use
descript
inferenti
method
test
use
determin
data
nongaussian
depend
distribut
data
continu
variabl
evalu
use
student
test
analysi
varianc
wilcoxon
rank
sum
test
analysi
varianc
use
assess
differ
fecal
oocyst
count
fecal
consist
score
treat
untreat
calv
effect
comorbid
outcom
interest
evalu
use
student
test
data
analyz
use
jmp
pro
sa
institut
inc
